Health-care companies ticked up as traders rotated into the defensive sector.
Private-equity firms have sharply slowed their serial acquisitions of smaller medical businesses, succumbing to pressure from the Federal Trade Commission over allegations that surgery "rollups" unfairly reduced competition and harmed patients.
Viking Therapeutics stock crumbled despite seemingly positive test results for a drug that treats a serious liver disease.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
06-04-24 1658ET
